Subject Area
Dermatology
Article Type
Original Study
Abstract
Background: A depigmenting skin condition called vitiligo affects 0.5–2 percent of people globally. It seems to be caused by an interaction between neurological, immunological, and genetic factors. Vitiligo is mediated by cell-mediated reactions, as Th1/Th17 and Tc1 cells. It is thought that the Th17 cell's most specialized cytokine isIL-22. Aim: To explore the blood levels of IL-22 in non-segmental vitiligo and to investigate whether it can be a biomarker in monitoring disease activity and it’s correlation with disease severity. Patient and methods: This study included thirty healthy individuals and sixty non-segmental vitiligo cases (30 with stable vitiligo and 30 with active vitiligo). Vitiligo Extent Score (1) (1) was needed for estimation of affected body surface area. IL-22 serum levels were estimated using ELISA. Results: When comparing cases with active vitiligo to those with stable vitiligo, the IL-22 median serum level in the former group was statistically significantly elevated (p
Recommended Citation
Dakrory, Fatma Faisal El; Elsayed, Maha Elsayed Mahmoud; Sadeq, Yousra Ibrahim El-tantawy; and Alashry, Shereen Ezzalregal
(2024)
"Serum Interleukin-22 in non-segmental Vitiligo,"
Mansoura Medical Journal: Vol. 53
:
Iss.
1
, Article 13.
Available at:
https://doi.org/10.58775/2735-3990.1412
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
